Consultant in Paediatric & Adolescent Oncology Drug Development.
Permanent, Full Time (10PA).
£77,913 - £105,042 per annum.
The Oak Centre for Children and Young People is one of the largest comprehensive children’s cancer centres in Europe, and the principal treatment centre for all children with cancer in the South Thames area. It is also home to one of Europe’s largest and leading drug development programmes in paediatric oncology. We also have one of the largest stem cell transplant services for patients with malignant disease in the UK.
The Children’s and Young People’s Unit at The Royal Marsden is fully integrated with all adult oncology specialities and enjoys the benefits of co-location with The Institute of Cancer Research (ICR) on our Sutton site.
Over the past eleven years, via the Royal Marsden Cancer Charity (RMCC), funding from The Oak Foundation has facilitated the development of a strong purpose-built Paediatric and Adolescent Drug Development Team of at least 25 dedicated individuals with expertise and knowledge in the field of drug development. Oak Foundation funding has provided pivotal staff, and additional staff are funded via other sources such as the NIHR BRC, the Paediatric ECMC network and other charity donors. The Oak-funded team includes the Oak Foundation Consultant in Paediatric and Adolescent Oncology Drug Development post, two part-time research nurses, one part time clinical trial co-ordinator, an academic personal assistant to the Drug Development Team and a clinical fellow in radiology to work specifically in the area of paediatric early phase trials and functional imaging; there are three dedicated Drug Development Fellows and additional research nurses, trial co-ordinators, data managers, and a tissue collector funded via other sources (Details are provided in Appendix A).
Several of the existing NHS consultants work closely with the team taking on investigator or sub-investigator responsibility for the organisation and recruitment for some of the tumour-specific early phase trials. This supporting infrastructure has allowed the paediatric early phase clinical trials portfolio to increase from just 2 open studies in 2006 to upward of 25 studies open or in late set-up in 2017/8. This is one of the largest portfolios of paediatric early phase trials in Europe.
To apply for this post please click the apply button
Quoting reference number 282-C6002AAC. You are required to provide a copy of your CV when submitting your application form.
For further discussion about the post please contact: Dr Donna Lancaster, Head of Paediatric Oncology at RMH – 020 8661 3594 Dr Lynley Marshall, Oak Foundation Consultant in Paediatric and Adolescent Oncology Drug Development - 020 8661 3678
Closing Date: 6th December 2018